There was no significant difference in the penetrance of CHEK2 PTV vs PMV for cancers in MyCode (univariate HR, 1.06 [95% CI, 0.90-1.25]; P = .47) and the UKBB (adjusted HR, 1.15 [95% CI, 1.00-1.33]; P = .05). This evidence concerns the gene CHEK2 and cancer.